2019 | 2018 | 2017 | 2016 | 2015

La Jolla Pharmaceutical Company Announces Notice of Allowance for U.S. Patent Covering LJPC-501

11/30/15

Patent Term Extends to 2034 SAN DIEGO--(BUSINESS WIRE)--Nov. 30, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to s

Read More

La Jolla Pharmaceutical Company Announces Third Quarter 2015 Financial Results and Recent Corporate Progress

11/06/15

SAN DIEGO--(BUSINESS WIRE)--Nov. 6, 2015-- La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patient

Read More

La Jolla Pharmaceutical Company Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload

10/19/15

SAN DIEGO--(BUSINESS WIRE)--Oct. 19, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patien

Read More

La Jolla Pharmaceutical Company Closes Offering of Common Stock

09/15/15

SAN DIEGO--(BUSINESS WIRE)--Sep. 15, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients

Read More

La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401

09/11/15

EMA Innovation Task Force Meeting Granted SAN DIEGO--(BUSINESS WIRE)--Sep. 11, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"), a leader in the development of innovative therapies in

Read More

La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock

09/10/15

SAN DIEGO--(BUSINESS WIRE)--Sep. 10, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients

Read More

La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock

09/09/15

SAN DIEGO--(BUSINESS WIRE)--Sep. 9, 2015-- La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients s

Read More

La Jolla Pharmaceutical Company Receives Orphan Drug Designation for Two Novel Compounds for Fibrodysplasia Ossificans Progressiva

08/18/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors

08/18/15

Novel Compounds Have Therapeutic Potential in Broad Range of Diseases, Including Certain Rare Genetic Disorders SAN DIEGO & NASHVILLE, Tenn.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla),

Read More

La Jolla Pharmaceutical Company Announces FDA Acceptance of IND for LJPC-401

08/11/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Second Quarter 2015 Financial Results and Recent Corporate Progress

08/07/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Exclusive Worldwide License Agreements Covering LJPC-30Sa and LJPC-30Sb

08/05/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

Lakhmir S. Chawla, M.D. Receives the International Vicenza Award

07/01/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at the JMP Securities Life Science Conference 2015

06/17/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

a Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2015 Global Healthcare Conference

05/27/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Acquires Rights to Next-Generation Gentamicin Derivatives

05/07/15

Conference Call and Webcast at 8:00 AM Eastern Time on Friday, May 8 SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended

Read More

La Jolla Pharmaceutical Company Announces Portfolio Reprioritization

05/07/15

Conference Call and Webcast at 8:00 AM Eastern Time on Friday, May 8 SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended

Read More

La Jolla Pharmaceutical Company Announces First Quarter 2015 Financial Results and Corporate Highlights

04/29/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Appoints Lakhmir S. Chawla, M.D., as Chief Medical Officer

04/27/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Additions to LJPC-401 Advisory Board

04/22/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-thr

Read More

La Jolla Pharmaceutical Company Appoints Dennis Mulroy as Chief Financial Officer

04/06/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension

03/24/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Initiation of Phase 2b Clinical Trial of GCS-100 in Advanced Chronic Kidney Disease

03/18/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate Highlights

03/16/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces Special Protocol Assessment for Planned Phase 3 Trial of LJPC-501 in Catecholamine-Resistant Hypotension

02/09/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company to Provide Corporate Overview at 17th Annual BIO CEO & Investor Conference

02/04/15

SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More



Print Page Print PageE-mail Page E-mail PageRSS Feeds RSS FeedsE-mail Alerts E-mail AlertsIR Contacts IR Contacts